Inactive/Delisted stock

Lyell Immunopharma Stock (NASDAQ:LYEL)


Chart

Previous Close

$11.46

52W Range

$7.65 - $53.50

50D Avg

$9.07

200D Avg

$16.13

Market Cap

$188.95M

Avg Vol (3M)

$86.93K

Beta

-0.27

Div Yield

-

LYEL Company Profile


Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

300

IPO Date

Jun 17, 2021

Website

LYEL Performance


Peer Comparison


TickerCompany
MLYSMineralys Therapeutics, Inc.
MRUSMerus N.V.
CRNXCrinetics Pharmaceuticals, Inc.
RVMDRevolution Medicines, Inc. Warrant
KRONKronos Bio, Inc.